These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21262425)

  • 21. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular-weight heparin in oncology.
    Zacharski LR; Loynes JT
    Anticancer Res; 2003; 23(3C):2789-93. PubMed ID: 12926114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
    Ornstein DL; Hong-Dice YG; Papini JR
    Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of deep vein thrombosis using low-molecular-weight heparins.
    Groce JB
    Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
    Prandoni P; Simioni P; Pagnan A
    Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.
    Cohen M; Jeske WP; Nicolau JC; Montalescot G; Fareed J
    J Thromb Thrombolysis; 2012 Apr; 33(3):230-8. PubMed ID: 22234748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommendations on biosimilar low-molecular-weight heparins.
    Harenberg J; Kakkar A; Bergqvist D; Barrowcliffe T; Casu B; Fareed J; Mismetti P; Ofosu FA; Raake W; Samama M; Schulman S;
    J Thromb Haemost; 2009 Jul; 7(7):1222-5. PubMed ID: 19323788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of generic low molecular weight heparins: a perspective.
    Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venous thromboembolism in the medically ill patient: a call to action.
    Bergmann JF; Kher A
    Int J Clin Pract; 2005 May; 59(5):555-61. PubMed ID: 15857352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
    Fareed J; Haas S; Sasahar A
    Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low molecular weight heparins copies: are they considered to be generics or biosimilars?
    Minghetti P; Cilurzo F; Franzé S; Musazzi UM; Itri M
    Drug Discov Today; 2013 Mar; 18(5-6):305-11. PubMed ID: 23153556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic and commercial low molecular weight heparins.
    Messmore HL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):253. PubMed ID: 16959678
    [No Abstract]   [Full Text] [Related]  

  • 37. Low molecular weight heparin in pregnancy: current issues.
    Greer I; Hunt BJ
    Br J Haematol; 2005 Mar; 128(5):593-601. PubMed ID: 15725079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF; Hull RD
    Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
    Nicolau JC; Cohen M; Montalescot G
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.